Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | GAA | P10253 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9802440 | 0.88 | GAA (0.71) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL6921588 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAMEN1KMT2ACYP1A2 | |
| SCHEMBL19850673 | 0.75 | GAA (0.57) | SMN1; SMN2GAAMEN1KMT2ACYP1A2 | |
| SCHEMBL9786463 | 0.75 | GAA (0.57) | SMN1; SMN2GAAMEN1KMT2ACYP1A2 | |
| SCHEMBL19850671 | 0.74 | SMN1; SMN2 (0.64) | SMN1; SMN2GAAMEN1KMT2ACYP1A2 | |
| SCHEMBL1169368 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAMEN1KMT2ACYP1A2 | |
| SCHEMBL28558069 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAALDH1A1TSHROPRM1 | |
| SCHEMBL17785187 | 0.73 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAALDH1A1TSHROPRM1 | |
| SCHEMBL15540959 | 0.73 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAALDH1A1TSHROPRM1 | |
| SCHEMBL10502644 | 0.72 | GAA (0.54) | SMN1; SMN2GAAMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542687-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004028538-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2004-04-08 | — | — | US | claimed |
| EP-1542687-B1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-1901744-A2 | PREPARATIONS COMPRISING ARYLAZINE SUBSTITUTED WITH A CARBONYLIC MOIETY TO INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070049559-A1 | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2007-03-01 | — | — | US | disclosed |
| WO-2007002781-A2 | PREPARATIONS COMPRISING ARYLAZINE SUBSTITUTED WITH A CARBONYLIC MOIETY TO INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2007-01-04 | — | — | WO | disclosed |
| US-7071211-B2 | Small organic molecules that increase the activity of gelatinase a in ocular cells | BAUSCH & LOMB INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060121090-A1 | Ocular compositions that increases the activity of gelatinase a in ocular cells | BAUSCH & LOMB INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| EP-1542687-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004028538-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2004-04-08 | — | — | US | disclosed |
| EP-0222163-B1 | PROCESS FOR THE MANUFACTURE OF GAMMA-BUTYROLACTAMES | BAYER AG (DE) | 1989-07-19 | — | — | EP | disclosed |
| EP-0219055-B1 | PROCESS FOR THE MANUFACTURE OF CLAUSENAMIDE | BAYER AG (DE) | 1989-06-07 | — | — | EP | disclosed |
| US-4803285-A | ANTIAMNESIC AGENTS | BAYER AKTIENGESELLSCHAFT & CHINESE (DE) | 1989-02-07 | — | — | US | disclosed |
| US-4751315-A | Process for the preparation of clausenamide | BAYER AKTIENGESELLSCHAFT (DE) | 1988-06-14 | — | — | US | disclosed |
| US-4731455-A | Process for the preparation of gamma-butyrolactams | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-15 | — | — | US | disclosed |
| US-4731456-A | Process for the preparation of clausenamide | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-15 | — | — | US | disclosed |
| EP-0222163-A1 | Process for the manufacture of gamma-butyrolactames | BAYER AG (DE) | 1987-05-20 | — | — | EP | disclosed |
| EP-0219055-A1 | Process for the manufacture of clausenamide | BAYER AG (DE) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060121090-A1 | Ocular compositions that increases the activity of gelatinase a in ocular cells | MMP3, MMP13, MMP1 | SMN1; SMN2 4791/4885GAA 195/4885MEN1 1788/4885 |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | MMP1, MMP3, MMP10 | SMN1; SMN2 4847/4885GAA 165/4885MEN1 2428/4885 |
| US-20070049559-A1 | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells | MMP1, MMP17, MMP15 | SMN1; SMN2 4702/4885GAA 427/4885MEN1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.